Metabolon, Inc., a leader in metabolomics solutions, has reached a significant milestone by being cited in over 4,000 peer-reviewed publications. This achievement highlights the growing importance of metabolomics in various life sciences applications, including diagnostics, therapeutic development, and precision medicine. The announcement was made on October 7, 2025, from the company’s headquarters in Morrisville, North Carolina.
The extensive citations of Metabolon’s services reflect the increasing integration of metabolomics within global multiomics studies. Publications referencing Metabolon’s work have appeared in prestigious journals such as Nature, Nature Medicine, Nature Genetics, Cell, and the Proceedings of the National Academy of Sciences (PNAS). These citations underscore the essential role of metabolomics in advancing scientific research.
Metabolomics: A Transformative Tool in Research
According to Ro Hastie, CEO of Metabolon, “Metabolomics has become a standard inclusion in cutting-edge multiomics research. We’re seeing this across all customer segments globally.” The rapid growth in citations illustrates the transformative impact of metabolomics across diverse scientific fields. Hastie emphasized that studies lacking metabolomics may miss vital biological insights. Metabolon’s Level 1 metabolomics library and services provide a comprehensive foundation for researchers engaged in multiomics studies.
Metabolon operates an ISO 9001 and CAP-accredited laboratory, ensuring compliance with enterprise-grade standards. The company has conducted over 15,000 studies globally, collaborating with leading pharmaceutical, biotechnology, academic, and government institutions. This robust infrastructure and established reputation enable Metabolon to advance precision health across various sectors, including biopharma, population health, consumer goods, agriculture, wellness, and academic research.
Understanding Metabolomics and Its Applications
Metabolomics, the extensive study of small molecules within biological systems, offers a functional overview of biological states. This technology allows researchers to examine not only genetic variations but also the impact of external factors, such as drugs, diet, lifestyle, and microbiome interactions on health. By measuring thousands of discrete chemical signals that constitute biological pathways, metabolomics can identify crucial biomarkers. These biomarkers facilitate a deeper understanding of drug mechanisms, pharmacodynamics, safety profiles, and individual therapeutic responses.
Metabolon, with over 25 years of experience, has developed industry-leading scientific, technological, and bioinformatics methods. The company’s Global Discovery Panel is backed by the world’s largest proprietary metabolomics reference library, enhancing its capacity to support diverse research initiatives. With scalable and customizable multiomics solutions, Metabolon aids clients from initial discovery through clinical trials and product lifecycle management.
For more information about Metabolon’s services, visit their Global Discovery Panel and guide to multiomics available on their website.
